Home / Information / Lorlatinib
Lorlatinib
Lorlatinib is a 3rd generation TKI developed by Pfizer. The recommended dose is 100mg taken daily.
A comprehensive website by Pfizer, the manufacturer of Lorlatinib
Documents
Name
Summary of Contents
Action
Managing Lorlatinib Together
NEW
An overview and practical guide for patients by ALK-positive patients and medical experts.
Increased cardiovascular risk with Lorlatinib
NEW
Patients receiving lorlatinib have an increased risk of developing cardiovascular diseases, particularly heart failure and stroke.
Management of Side Effects
A guide for health care professionals on the management of adverse effects arising from Lorlatinib.
Use of Lorlatinib with Paxlovid
Paxlovid is used to treat early Covid-19 infections. Here is Pfizer's statement about using it with Lorlatinib.
Crown Study 7-year Outcomes
Plain English report, co-authored by Debra Montague, Chair, ALK Positive UK
Crown Study - more information
Lorlatinib doesn't work for about 20% of patients. This is a plain English artificially generated summary of a report that explains why that might be.
Lorlatinib What to Expect (Pfizer)
A booklet from Pfizer on the side effects that patients may experience.
Weight Gain
Patients with weight gain of over 5% within 6 months developed significantly higher maximum gain
Lorlatinib - An Oncologist's Opinion
A discussion with Dr Camidge, a leading USA ALK+ expert.